Mi­cro­bio­me pi­o­neer Seres crushed as lead drug flops in PhII

One of the pi­o­neers in the mi­cro­bio­me R&D world has slammed in­to a Phase II fail­ure for its lead pro­gram. Seres Ther­a­peu­tics $MCRB says that SER-109 flunked a mid-stage test for re­duc­ing the re­cur­rence of Clostrid­i­um dif­fi­cile in­fec­tion.

SER-109 bare­ly im­proved on the per­for­mance of a place­bo in the study, with 44% in the mi­cro­bio­me drug arm see­ing a re­cur­rence of CDI, com­pared to 53% in the sug­ar pill group. That’s not near­ly good enough to qual­i­fy as a sig­nif­i­cant im­prove­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER